Loading...
Market
Which disease will AlphaProteo target in its first major clinical application by the end of 2024?
2
Resolution / Starting Odds
Cancer • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Other • 25%
Clinical trial registries, official announcements from Google DeepMind or partnering pharmaceutical companies
Story
Google DeepMind Unveils AlphaProteo for High-Strength Protein Binders with 3-300x Better Affinities
Sep 5, 2024, 03:24 PM
Google DeepMind has unveiled AlphaProteo, a new AI system designed to create novel, high-strength protein binders that target specific molecules. AlphaProteo achieves 3-300x better binding affinities and success rates on 7 targets compared to existing methods, making it a significant advancement in drug development, disease diagnosis, and biosensor technology. This system could accelerate the understanding of biological processes and aid in the development of new therapies. AlphaProteo's capabilities, trained on synthetic data from AlphaFold, are expected to outperform existing methods in binding proteins, potentially revolutionizing the field of biotechnology.
View original story
Similar markets
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Drug Development • 25%
Agricultural Biotechnology • 25%
Industrial Enzymes • 25%
Other • 25%
Yes • 50%
No • 50%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Cancer • 25%
Cardiovascular diseases • 25%
Neurological disorders • 25%
Other • 25%
Yes • 50%
No • 50%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Cardiovascular disease • 25%
Diabetes • 25%
Cancer • 25%
Other • 25%
Inflammatory Bowel Disease • 25%
Obesity • 25%
Diabetes • 25%
Other • 25%